{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T21:31:15Z","timestamp":1775770275229,"version":"3.50.1"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"unspecified","delay-in-days":47,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Boston Scientific","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gedeon Richter Plc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017647","name":"ResMed","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100017647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Menarini","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"MSD","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Abbott","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100004334","name":"Merck & Co.","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Bristol Myers Squibb and Pfizer Alliance","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2024,9,19]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hypertrophic cardiomyopathy (HCM) is commonly associated with atrial fibrillation (AF), but its impact on outcomes in real-world practice is uncertain. The aim of the study was to evaluate the clinical profile and prognosis of patients with HCM and AF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Overall, 1739 adult patients with HCM (40.9% women; median age: 55.5 years) were enrolled in the EURObservational Research Programme (EORP) Cardiomyopathy\/Myocarditis Registry. Clinical characteristics at baseline and cardiovascular endpoints at 1\u2009year were prospectively assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, AF was present in 478 (27.5%) patients; an additional 48 patients (2.8%) developed AF at 1-year follow-up<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www2.cloud.editorialmanager.com\/eupc\/SubManuscriptData.aspx?SessionThreadIdField=d4d56849-7e8a-4253-aaef-f25bf8645249\">. <\/jats:ext-link>Oral anticoagulants (OAC) were administered at baseline in 69.5% of the patients. Patients with AF were older and more symptomatic, had higher body mass index, more prevalent cardiovascular risk factors, a history of sustained ventricular tachycardia and implantable cardioverter-defibrillator, lower left ventricular ejection fraction (LVEF), larger left atria (LA) and more advanced LV diastolic dysfunction (pp&lt;0.001 for all). Age at enrolment (OR=1.068, p&lt;0.001), symptom: palpitations (OR=2.191, p&lt;0.001), LVEF (OR=0.978, p&lt;0.001) and LA diameter (OR=1.094, p&lt;0.001) were independent predictors of AF in HCM population. Patients with AF had a higher annual incidence of stroke\/transient ischaemic attack (2.6 vs 0.9%, p=0.009) and a trend towards increased all-cause mortality in comparison to the non-AF cohort (3.4 vs 1.7%, p=0.053).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>AF affects nearly one-third of patients with HCM and is associated with higher symptom burden, increased prevalence of comorbidities, myocardial remodelling and increased annual risk of cerebral ischaemic events. In spite of this, the utilisation of OAC was suboptimal.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2024-002876","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T17:56:09Z","timestamp":1739814969000},"page":"e002876","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Hypertrophic cardiomyopathy and atrial fibrillation: the Cardiomyopathy\/Myocarditis Registry of the EURObservational Research Programme of the European Society of Cardiology"],"prefix":"10.1136","volume":"12","author":[{"given":"Katarzyna","family":"Mizia-Stec","sequence":"first","affiliation":[{"name":"First Department of Cardiology, Medical University of Silesia School of Medicine in Katowice, Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-1754","authenticated-orcid":false,"given":"Juan R","family":"Gimeno","sequence":"additional","affiliation":[{"name":"Cardiac Department, Virgen de la Arrixaca University Hospital, El Palmar, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1782-1118","authenticated-orcid":false,"given":"Philippe","family":"Charron","sequence":"additional","affiliation":[{"name":"Cardiology and Genetics, Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry M","family":"Elliott","sequence":"additional","affiliation":[{"name":"Cardiology, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Pablo","family":"Kaski","sequence":"additional","affiliation":[{"name":"Inherited Cardiovascular Diseases, Great Ormond Street Hospital for Children, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-6779","authenticated-orcid":false,"given":"Aldo Pietro","family":"Maggioni","sequence":"additional","affiliation":[{"name":"Research Center, ANMCO, Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Tendera","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Tavazzi","sequence":"additional","affiliation":[{"name":"Maria Cecilia Hospital SpA, Cotignola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1151-8385","authenticated-orcid":false,"given":"Maciej T","family":"Wybraniec","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Laroche","sequence":"additional","affiliation":[{"name":"EurObservational Research Programme Department, European Society of Cardiology, Sophia Antipolis, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alida","family":"Caforio","sequence":"additional","affiliation":[{"name":"Department of Cardiological Thoracic and Vascular Sciences, University of Padua, Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"2025081710091684000_12.1.e002876.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"2025081710091684000_12.1.e002876.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"2025081710091684000_12.1.e002876.3","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/ejhf.2979","article-title":"State-of-the-art document on optimal contemporary management of cardiomyopathies","volume":"25","author":"Seferovi\u0107","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025081710091684000_12.1.e002876.4","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1161\/CIRCRESAHA.122.319835","article-title":"Arrhythmias as Presentation of Genetic Cardiomyopathy","volume":"130","author":"Lukas Laws","year":"2022","journal-title":"Circ Res"},{"key":"2025081710091684000_12.1.e002876.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01727-2"},{"key":"2025081710091684000_12.1.e002876.6","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euab065"},{"key":"2025081710091684000_12.1.e002876.7","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-304276"},{"key":"2025081710091684000_12.1.e002876.8","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab648","article-title":"Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2025081710091684000_12.1.e002876.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx819"},{"key":"2025081710091684000_12.1.e002876.10","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.77.2.130"},{"key":"2025081710091684000_12.1.e002876.11","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1002\/ehf2.12854","article-title":"Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy\/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology","volume":"7","author":"Mizia\u2010Stec","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2025081710091684000_12.1.e002876.12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/europace\/euy064","article-title":"Atrial fibrillation in patients with inherited cardiomyopathies","volume":"21","author":"Yeung","year":"2019","journal-title":"Europace"},{"key":"2025081710091684000_12.1.e002876.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00434-8"},{"key":"2025081710091684000_12.1.e002876.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.06.024"},{"key":"2025081710091684000_12.1.e002876.15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.009796","article-title":"Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score","volume":"14","author":"Carrick","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2025081710091684000_12.1.e002876.16","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134484","article-title":"Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy","volume":"12","author":"Stec","year":"2023","journal-title":"J Clin Med"},{"key":"2025081710091684000_12.1.e002876.17","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309672"},{"key":"2025081710091684000_12.1.e002876.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196612","article-title":"Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany-An analysis of over 5 million patients","volume":"13","author":"Husser","year":"2018","journal-title":"PLoS One"},{"key":"2025081710091684000_12.1.e002876.19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.amjcard.2021.08.024","article-title":"Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based Claims Analysis)","volume":"159","author":"Butzner","year":"2021","journal-title":"Am J Cardiol"},{"key":"2025081710091684000_12.1.e002876.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227012","article-title":"Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study","volume":"15","author":"Moon","year":"2020","journal-title":"PLoS ONE"},{"key":"2025081710091684000_12.1.e002876.21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijcard.2018.05.034","article-title":"Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry","volume":"271","author":"Boriani","year":"2018","journal-title":"Int J Cardiol"},{"key":"2025081710091684000_12.1.e002876.22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ahj.2017.08.011","article-title":"International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries","volume":"194","author":"Steinberg","year":"2017","journal-title":"Am Heart J"},{"key":"2025081710091684000_12.1.e002876.23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx730"},{"key":"2025081710091684000_12.1.e002876.24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw233"},{"key":"2025081710091684000_12.1.e002876.25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0038-1676818","article-title":"Hypertrophic Cardiomyopathy in Patients with Atrial Fibrillation: Prevalence and Associated Stroke Risks in a Nationwide Cohort Study","volume":"119","author":"Jung","year":"2019","journal-title":"Thromb Haemost"},{"key":"2025081710091684000_12.1.e002876.26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"2025081710091684000_12.1.e002876.27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.15420\/aer.2017:4:2","article-title":"Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy","volume":"6","author":"Camm","year":"2017","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"2025081710091684000_12.1.e002876.28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm342"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2024-002876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T17:09:29Z","timestamp":1755450569000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2024-002876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,17]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/openhrt-2024-002876"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2024-002876","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}